Loading
A plain map of the steps a new cancer drug passes through in Canada, from Health Canada's licence and the federal price ceiling through the national value review and joint price negotiation to each province's decision to pay.
A review of the regulatory and funding process for cancer drugs in Canada, covering Health Canada, the Patented Medicine Prices Review Board, health technology assessment by CADTH (and INESSS in Quebec), the pan-Canadian Pharmaceutical Alliance and the provincial, territorial and federal payers, with recent changes and options to reduce duplication and delay.
It records that the three westernmost provinces fund all cancer drugs, oral and intravenous, while in Ontario and eastern Canada oral drugs go through provincial drug plans and intravenous ones through cancer programmes, and Quebec funds intravenous drugs through hospital budgets; that the Patented Medicine Prices Review Board reported cancer drug spending tripling to $3.9 billion in 2019, 14.6 per cent of the drug market; that Health Canada generally commits to a standard decision within 300 days and 180 for priority review; that CADTH targets about 200 days from screening to final recommendation; and that the pan-Canadian Pharmaceutical Alliance publishes no formal negotiation timelines or decision criteria.
Approval in Canada is not access: a licensed cancer drug still has to pass a value review, a joint price negotiation and a provincial listing, and where you live decides how a take-home drug is paid for.
Shares Canada's Drug Agency (CDA-AMC), Current oncology, Health Canada.
Shares Canada's Drug Agency (CDA-AMC), Current oncology, Health Canada.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/